What does this research mean for the field?

Short-term estrogen therapy does not increase the recurrence of endometrial polyps in women with intrauterine adhesions. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine if short-term estrogen therapy affects recurrence of intrauterine adhesions and endometrial polyps after surgery.

March 13, 2026Open Access

Impact of Short-Term Estrogen Therapy on Endometrial Polyps Recurrence in Women with Intrauterine Adhesion and Endometrial Polyps: A Retrospective Cohort Study

Puntos clave

To determine if short-term estrogen therapy affects recurrence of intrauterine adhesions and endometrial polyps after surgery.
Retrospective cohort study design
Included women aged 18-45 with intrauterine adhesions and endometrial polyps
Analyzed three postoperative regimens: sequential therapy, combined oral contraceptive, or no hormonal therapy
Recurrence confirmed via transvaginal ultrasound and/or hysteroscopy
Compared outcomes based on treatment groups
166 women included in the analysis
Recurrence rates were 6.6% for intrauterine adhesions and 4.8% for endometrial polyps
No significant differences in recurrence rates or pregnancy outcomes among the treatment groups (P > 0.05)
Baseline polyp multiplicity differed, with more multiple polyps in combined oral contraceptive group

Resumen

Objective: To investigate whether short-term postoperative estrogen-related therapy is associated with recurrence of intrauterine adhesions (IUA), endometrial polyps (EPs), and pregnancy outcomes in women with concomitant IUA and EPs. Methods: This single-center retrospective cohort study included women (18– 45 years) diagnosed with both IUA and EPs who underwent concurrent hysteroscopic transcervical resection of adhesions (TCRA) and polypectomy from January 2019 to June 2024. Patients were grouped by postoperative regimen: (1) estradiol–dydrogesterone sequential therapy (Femoston; estradiol 2 mg/dydrogesterone 10 mg; 2– 3 months), (2) combined oral contraceptive (Yaz; ethinylestradiol 0.02 mg/drospirenone 3 mg; 3 months), or (3) no hormonal therapy. Recurrence was confirmed by transvaginal ultrasound and/or hysteroscopy. Results: A total of 166 women were included (sequential therapy, n=47; COC, n=32; no hormone, n=87). Baseline polyp multiplicity differed among groups (P=0.003), with a higher proportion of multiple EPs in the COC group. Postoperative IUD/balloon placement also differed among groups (P=0.012). Overall recurrence rates were 6.6% for IUA and 4.8% for EPs. No statistically significant differences were observed among groups in postoperative menstrual changes, recurrence rates, time to recurrence, or pregnancy outcomes (all P> 0.05). Follow-up duration did not differ significantly among groups. Conclusion: In this retrospective cohort, no statistically significant differences were observed among short-term sequential estrogen–progestin therapy, COC use, and no hormonal therapy with respect to IUA recurrence, EP recurrence, or pregnancy outcomes. Short-term estradiol–dydrogesterone therapy was not associated with increased EP recurrence in women with IUA and a single EP. These findings are observational and should be confirmed in prospective studies. Keywords: intrauterine adhesions, endometrial polyps, estrogen, recurrence, pregnancy outcomes

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo